Updates are available Correction dated 2024-09-17
Click to view Correction: https://doi.org/10.1038/s41467-024-52439-7
-
Authors
Tribble, James R. https://orcid.org/0000-0001-8301-7358
Jöe, Melissa https://orcid.org/0000-0001-8516-4706
Varricchio, Carmine
Otmani, Amin
Canovai, Alessio https://orcid.org/0009-0007-9229-4710
Habchi, Baninia https://orcid.org/0000-0001-9705-167X
Daskalakis, Evangelia
Chaleckis, Romanas https://orcid.org/0000-0001-8042-1005
Loreto, Andrea https://orcid.org/0000-0001-6535-6436
Gilley, Jonathan
Wheelock, Craig E. https://orcid.org/0000-0002-8113-0653
Jóhannesson, Gauti
Wong, Raymond C. B. https://orcid.org/0000-0002-8092-9455
Coleman, Michael P. https://orcid.org/0000-0002-9354-532X
Brancale, Andrea https://orcid.org/0000-0002-9728-3419
Williams, Pete A. https://orcid.org/0000-0001-6194-8397
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-02124, 2022-00799)
- License Information
-
More Information
Article History
Received: 12 May 2023
Accepted: 19 June 2024
First Online: 24 July 2024
Change Date: 17 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-52439-7
Competing interests
: PAW is an inventor on an awarded US patent held by The Jackson Laboratory for nicotinamide treatment in glaucoma (“Treatment and prevention of ocular neurodegenerative disorder”, US11389439B2). PAW, MJ, CV, and AB are inventors on a submitted patent held by Mim Neurosciences AB for novel NMNAT2-targeting small molecules. All other authors declare that they have no competing interests.
